Finance

Lists
Outlook: 41.7% bullish·0.0% bearish
Go to analysis
LFCR:NASDAQ
Lifecore Biomedical Inc
$6.54
+0.15%
(+0.0100) 1D
$6.50
-0.59% (-0.038)
After hours
Closed: Oct 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LFCR...
Open
$6.55
High
$6.55
Low
$6.53
Mkt. cap
247.90M
Avg. vol.
336.53K
Volume
504.72K
52-wk high
$8.98
52-wk low
$3.62
EPS
-$1.15
Beta
0.98
Shares outstanding
37.91M
No. of employees
400
Open
$6.55
High
$6.55
Low
$6.53
Mkt. cap
247.90M
Avg. vol.
336.53K
Volume
504.72K
52-wk high
$8.98
52-wk low
$3.62
EPS
-$1.15
Beta
0.98
Shares outstanding
37.91M
No. of employees
400
News stories
From web sources and news partners
About Lifecore Biomedical Inc
CEO-
Employees400
Founded1965
Headquarters-
SectorHealth care
Websitelifecore.com
Analyst ratings
Based on 4 analysts giving stock ratings to LFCR in the past 3 months
Hold
Buy
0
Hold
4
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for LFCR in the last 3 months.
Highest
Current $6.54
$6.28 (-3.98%)
Average
$6.28 (-3.98%)
Lowest
$6.28 (-3.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Petusky
Barrington
Hold
Maintained
-
-
10/01/2026
Matt Hewitt
Craig-Hallum
Hold
Downgraded
$6.28
-4%
09/29/2026
Jared Haase
William Blair
Hold
Downgraded
-
-
09/29/2026
Paul Knight
KeyBanc
Hold
Maintained
-
-
08/06/2026
Max Smock
William Blair
Buy
Reiterated
-
-
05/06/2026
Steven Etoch
Stephens
Hold
Reiterated
$5.00
-23.5%
03/17/2026
Last report
Mar 20, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.12 / -$0.20
+38.45%beat
Revenue / Est. (USD)
34.17M / 32.02M
+6.72%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
May 2025
Sep 2025
Mar 2026
Jun 2026
Revenue
35.75M
31.11M
23.19M
34.17M
Cost of goods sold
22.46M
23.32M
18.73M
22.09M
Cost of revenue
22.98M
23.32M
18.73M
22.09M
Research and development expenses
2.30M
1.96M
1.22M
1.54M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.98M
8.90M
6.32M
7.97M
Operating expense
11.08M
10.86M
7.53M
9.51M
Total operating expenses
32.82M
34.18M
26.26M
31.60M
Operating income
2.92M
-3.07M
-3.07M
2.57M
Other non operating income
-964.00K
-267.00K
-3.04M
-1.09M
EBT including unusual items
-5.10M
-9.66M
-14.94M
-6.13M
EBT excluding unusual items
-5.10M
-9.66M
-13.34M
-6.13M
Income tax expense
33.00K
333.00K
43.00K
23.00K
Effective tax rate
-0.08%
-3.45%
-0.29%
-0.38%
Other operating expenses
-
-
-
-
Net income
-5.11M
-9.99M
-14.98M
-6.16M
Net profit margin
-3.15%
-32.12%
-64.59%
-18.02%
Earnings per share
-0.12
-0.19
-0.30
-0.12
Interest and investment income
113.00K
58.00K
128.00K
144.00K
Interest expense
-7.18M
-6.38M
-7.35M
-7.75M
Net interest expenses
-5.52M
-6.33M
-7.22M
-7.61M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.30M
-1.09M
-762.00K
5.08M
Gain or loss from assets sale
91.00K
7.64M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps